MX2022011879A - Derivados de trapidilo marcados isotopicamente. - Google Patents

Derivados de trapidilo marcados isotopicamente.

Info

Publication number
MX2022011879A
MX2022011879A MX2022011879A MX2022011879A MX2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A
Authority
MX
Mexico
Prior art keywords
isotopically
labelled
trapidil derivatives
parkinson
disease
Prior art date
Application number
MX2022011879A
Other languages
English (en)
Inventor
Hiroko Masamune
Warren S Wade
Aarash Bordbar
Original Assignee
Sinopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinopia Biosciences Inc filed Critical Sinopia Biosciences Inc
Publication of MX2022011879A publication Critical patent/MX2022011879A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan derivados de trapidilo marcados isotópicamente útiles para el tratamiento de la enfermedad de Parkinson y los trastornos del movimiento asociados con la enfermedad de Parkinson. Los derivados de trapidilo marcados isotópicamente incluyen derivados de trapidilo deuterados. Adicionalmente, se proporcionan terapias combinadas de derivados de trapidilo marcados isotópicamente y agentes terapéuticos adicionales para el tratamiento de la enfermedad de Parkinson y los trastornos del movimiento asociados con la enfermedad de Parkinson.
MX2022011879A 2020-03-26 2021-03-25 Derivados de trapidilo marcados isotopicamente. MX2022011879A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000347P 2020-03-26 2020-03-26
US202063063846P 2020-08-10 2020-08-10
PCT/US2021/024226 WO2021195425A1 (en) 2020-03-26 2021-03-25 Isotopically-labelled trapidil derivatives

Publications (1)

Publication Number Publication Date
MX2022011879A true MX2022011879A (es) 2023-01-11

Family

ID=77892379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011879A MX2022011879A (es) 2020-03-26 2021-03-25 Derivados de trapidilo marcados isotopicamente.

Country Status (11)

Country Link
US (1) US20230102580A1 (es)
EP (1) EP4125853A1 (es)
JP (1) JP2023519289A (es)
KR (1) KR20230013023A (es)
CN (2) CN115916180A (es)
AU (1) AU2021244241A1 (es)
CA (1) CA3177066A1 (es)
IL (1) IL296788A (es)
MX (1) MX2022011879A (es)
TW (1) TW202202502A (es)
WO (1) WO2021195425A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100019470A (ko) * 2007-04-30 2010-02-18 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 １ 효소의 억제제
WO2017176652A2 (en) * 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
CA3087925A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Also Published As

Publication number Publication date
KR20230013023A (ko) 2023-01-26
CN115916180A (zh) 2023-04-04
CN116496279A (zh) 2023-07-28
JP2023519289A (ja) 2023-05-10
EP4125853A1 (en) 2023-02-08
WO2021195425A1 (en) 2021-09-30
US20230102580A1 (en) 2023-03-30
IL296788A (en) 2022-11-01
TW202202502A (zh) 2022-01-16
AU2021244241A1 (en) 2022-11-24
CA3177066A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
TW200509968A (en) Prevention and treatment of synucleinopathic disease
LUC00011I2 (es)
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2583978A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
CY1121683T1 (el) Προληψη και θεραπευτικη αγωγη συνουκλεϊνοπαθητικης και αμυλοειδογονου νοσου
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2021011488A (es) Compuestos y usos de estos.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2022011879A (es) Derivados de trapidilo marcados isotopicamente.
WO2023107552A3 (en) Purines and methods of their use
GB0410238D0 (en) Therapeutic agents
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2023003032A (es) Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer.
IL282562A (en) Composition and use for the treatment of parkinson's disease and related disorders
AU2020903624A0 (en) Methods and agents for the treatment of ocular disease
TR201900152T4 (tr) Sinükleinopatik ve amiloidojenik hastalıkların önlenmesi ve tedavisi.
EP4149500A4 (en) FIBROBLAST-BASED THERAPY FOR THE TREATMENT OF PARKINSON’S DISEASE
AU2013219147B2 (en) Uses of DPP-IV inhibitors